Skip to content
Loading…
Merck and Moderna announced positive results from a large late-stage trial of their personalized mRNA cancer vaccine, which significantly reduced the recurrence of melanoma, the deadliest form of skin cancer. Madison Muller reports on "Bloomberg Open Interest." (Source:…
To respect copyright, we link to the source rather than republishing the full text. Read the complete article on Bloomberg.